literature

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

PMID: 35458459 2022 Viruses

Discussion: (2009, 2010) showed a higher frequency of I84V, M154I, and V165I among ART-treated subtype B patients compared to ART-naive patients, implying that nonsuppressive ART treatment based on other antiretroviral drug classes (NRTI and/or NNRTI) might induce IN polymorphisms.

Discussion: Furthermore, our comparison of the HIVDR and no-HIVDR groups showed no differences (17.4%, 0.4%, and 7.3% of I84V, M154I, and V165I for the no-HIVDR group; and 22.6%, 1.1%, and 6.5% for the HIVDR group; p = 0.4, p = 0.5, and p = 1, respectively).

Discussion: However, in our study, no significant difference was found in I84V and

PMID: 34802406 2022 Current HIV research

Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.

PMID: 34694878 2022 Antimicrobial agents and chemotherapy

Table: I84I/V

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: I84V

Detection of Gag C-terminal mutations among HIV-1 non-B subtypes in a subset of Cameroonian patients.

PMID: 35082353 2022 Scientific reports

Table: I84V

Discussion: More precisely, Gag mutation P453L positively correlated with seven major protease resistance mutations (L33F, M46I, I54L, I54V, V82A, V82T, I84V).

Discussion: Several studies have shown a positive correlation of Gag P453L mutation with some protease major resistance mutations such as I50V and I84V.

Hybrid QM/MM Free-Energy Evaluation of Drug-Resistant Mutational Effect on the Binding of an Inhibitor Indinavir to HIV-1 Protease.

PMID: 35212226 2022 Journal of chemical information and modeling

Abstract: Here, we present a molecular simulation study on the ligand binding of indinavir, a potent transition state analogue inhibitor, to the wild-type protein and a V82T/I84V drug-resistant mutant of the HIV-1 protease.

Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

PMID: 33805099 2021 Biomolecules

Introduction: The major HIV-1 PI resistance mutations that affect the efficacy of boosted LPV regimen are V32I, L33F, M46I/L, I47V/A, I50V, I54V/T/A/L/M, L76V, V82A/F/T/S, I84V.

Discussion: These mutations, in the presence of active site mutations, like V82A and I84V, cause high-level cross-resistance to several HIV-1 PIs.

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

PMID: 33668946 2021 Pathogens (Basel, Switzerland)

Result: However, some minority DRMs at frequencies of 1%-5% disappeared, including N83D with PI-related, K70E, T215A, and K219E with NRTI-related and K101E, Y181C, H221Y and K238T with NNRTI-related, while others emerged, such as NNRTI-related V106A in patient GX088 at a frequency of 8.7%, and L23I, I47V and I84V with PI-related, D67N and

Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya: A cross-sectional study.

PMID: 34622871 2021 Medicine

Result: There were no other mutations at L76 V, I47 V, I50 V, I54 M/L, or I84 V.

Result: This study found no atazanavir resistance mutations (I50L, I84 V, or N88S).

Characterizing HIV-1 Genetic Subtypes and Drug Resistance Mutations among Children, Adolescents and Pregnant Women in Sierra Leone.

PMID: 34573296 2021 Genes

Result: We observed 4 PI-associated RAMs in 6 children/adolescents, as follows: the combination mutation I54V + V82A (n = 2), M46I/M (n = 1), and I84I/V (n = 1).